

# Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee

October 30, 2015

LAVAL, Quebec, Oct. 30, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that the ad hoc committee appointed by Valeant's board of directors has appointed former Deputy Attorney General of the United States Mark Filip of Kirkland & Ellis LLP to advise the committee in its review of allegations related to Valeant's business relationship with Philidor and related matters.

"We are pleased to have someone with Mark's distinguished qualifications advise our committee," stated Robert Ingram, Valeant's Lead Independent Director. "The committee will be meeting promptly to determine the work plan for its review in consultation with counsel."

## About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at [www.valeant.com](http://www.valeant.com).

## Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding appointment of former Deputy Attorney General of the United States and the scope of the Ad Hoc Committee's work. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

## Contact Information:

Laurie W. Little  
949-461-6002  
[laurie.little@valeant.com](mailto:laurie.little@valeant.com)

Elif McDonald  
905-695-7607  
[elif.mcdonald@valeant.com](mailto:elif.mcdonald@valeant.com)

Media:

Renee E. Soto / Meghan Gavigan  
Sard Verbinnen & Co.  
212-687-8080  
[rsoto@sardverb.com](mailto:rsoto@sardverb.com)  
/  
[mgavigan@sardverb.com](mailto:mgavigan@sardverb.com)

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/former-deputy-attorney-general-appointed-to-advise-valeants-ad-hoc-committee-300169412.html>

SOURCE Valeant Pharmaceuticals International, Inc.



### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)  
877-281-6642  
514-856-3855 (Canada)

### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)  
908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to  
the Legal Notice and Privacy Policy.  
©2026 Bausch Health Companies Inc. All rights  
reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY**  
**PERSONAL INFORMATION**